Osteoporosis Treatment Market Analysis & Forecast: 2025-2032

Osteoporosis Treatment Market Size and Trends

Global osteoporosis treatment market is estimated to be valued at USD 15.57 Bn in 2025 and is expected to reach USD 21.06 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2025 to 2032.

Discover market dynamics shaping the industry: Request sample copy

Introduction of novel therapeutics and self-administrable formulations are expected to boost the market growth. However, availability of generic medicines and patent expiration of blockbuster drugs may hamper the market growth. Emphasis on the development of anabolic drugs, osteoporosis treatment in premenopausal women, and rising awareness regarding the disease are expected to create lucrative opportunities for the market players in the near future.

Increasing Incidence of Osteoporosis

Increasing prevalence and incidence of osteoporosis is expected to drive the market growth during the forecast period. For instance, according to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 billion fractures annually worldwide, resulting in an osteoporosis fracture every 3 seconds.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Request sample copy

Increasing awareness campaigns is expected to drive the market growth over the forecast period. For instance, in February 2022, the Royal Osteoporosis Society, UK's national charity  launched a national campaign to raise awareness about osteoporosis and the importance of bone health among Parliamentarians and NHS leaders.

To learn more about this report, Request sample copy

The major factors that hinder growth of the global osteoporosis treatment market include product recalls and side effects associated with osteoporosis drugs such as pain in the joints, muscles, or bones, nausea, dizziness, etc. For instance, in April 2022, Macleods Pharmaceuticals Ltd., a pharmaceutical company, recalled 4,872 bottles of a drug used to treat or prevent osteoporosis, manufactured at Baddi (Himachal Pradesh), India due to failed content uniformity specifications.

Market Opportunity – Increasing Growth Strategies

Increasing adoption of inorganic growth strategies such as agreement is expected to offer lucrative growth opportunities over the forecast period. For instance, in February 2023, The World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) signed an agreement to develop a strategic roadmap on bone health and ageing and advocate for a public health strategy to prevent fractures among older people.

Discover high revenue pocket segments and roadmap to it: Request sample copy

Drug Type segment is sub-segmented into bisphosphonates, calcitonin, hormone therapy, selective estrogen receptor modulators (SERMs), parathyroid hormone-related protein (PTHrP) analog, and others. Bisphosphonates  segment is estimated to hold 32.6% of the market share in 2025 owing to its potent bone building properties. Bisphosphonates are synthetic analogs of pyrophosphate that bind strongly to the mineralized hydroxyapatite surface of bones. Once bound, bisphosphonates are slowly released from the bone surface and continue to inhibit osteoclast activity and reduce bone resorption. Due to their unique mechanism of action, bisphosphonates are able to significantly reduce fractures in patients with osteoporosis by inhibiting bone resorption and maintaining bone mineral density. Among the bisphosphonate class of drugs, alendronate and risedronate are commonly prescribed oral formulations that are highly effective in building bone mass. The strong clinical profile of bisphosphonates drives their use as the first line therapy, contributing to their leading market share.

Insights, By Route of Administration: Flexible Dosing Options, Oral Route Dominates

Route of Administration is sub-segmented into oral, injectable, others. Oral segment is estimated to hold 53.1% of the market share in 2025 owing to its flexible dosing options. The oral route is the most preferred method of delivery in osteoporosis treatment as it offers convenience of self-administration and flexible dosing schedules. Oral bisphosphonates like alendronate and risedronate which dominate the drug market, can be taken once-weekly or monthly. This flexible dosing regimen of oral bisphosphonates increases patient compliance compared to injections. Monthly and quarterly subcutaneous injections of denosumab have also improved adherence to treatment. However, frequent hospital visits are required for intravenous bisphosphonates like ibandronate injections, which impacts their demand. The ready availability of medications for oral self-administration at home addresses issues like repeat hospital visits and injections. This makes the oral route highly suitable for long-term treatment of osteoporosis, thereby, accounting for its large share in route of administration segment.

Insights, By Distribution Channel: Available Expertise and Monitoring Facilities

Distribution Channel segment is sub-segmented into hospital pharmacies, retail pharmacies, online pharmacies. Hospital pharmacies sub-segment is estimated to hold 41.9% of the market share in 2025 owing to available expertise and monitoring facilities. When initiating osteoporosis treatment, medical practitioners prefer recommending drugs through hospital pharmacies. Retail pharmacies and online pharmacies are feasible options for refilling prescriptions. Hospital pharmacies also carry the wider range of drugs and therapies to tackle challenging cases. Given the requirement of specialized care for osteoporosis management, patients rely on hospital pharmacies at the onset of treatment. This drives their large share in the distribution channel segment.

Regional Insights

Need a Different Region or Segment? Customize now

North America remains the dominant region in the global osteoporosis treatment market and is estimated to hold 39.7% of the market share in 2025. The U.S. accounts for the bulk of the market in North America due to favorable reimbursement policies and higher healthcare spending. Several leading global pharmaceutical companies are headquartered in the U.S. and have been actively investing in developing innovative drugs for bone health. This strong industry presence combined with aggressive marketing campaigns have kept awareness and diagnosis rates high in the region. Furthermore, the aging population and their higher disposable incomes make North America an attractive market.

The Asia Pacific region has emerged as the fastest growing market for osteoporosis treatment globally in recent years. Countries like China and Japan have aging societies which boosts prevalence of bone diseases. However, in many developing Asian countries, osteoporosis continues to be an under-diagnosed and under-treated condition. This large untreated patient base presents new opportunities for manufacturers. The presence of many global generics manufacturers in India and China is also pushing down treatment prices, making drugs more affordable. These lower costs coupled with improving access to healthcare infrastructure and rising standards of living means more patients can now access treatment. Governments are also launching awareness programs to educate people on bone health as the economic and healthcare burden of osteoporosis rises.

Market Report Scope

Osteoporosis Treatment Industry News

• In November, 2023, Apotex Inc., a pharmaceutical company, announced that they had launched Teriparatide Injection, a single-patient-use pre-filled pen used for the treatment of osteoporosis in the U.S. Teriparatide Injection is supplied as a single-patient-use pre-filled pen containing 250 mcg/mL, capable of administering 28 daily doses of 20 mcg per pen
• In April 2022, the International Osteoporosis Foundation, announced that they had launched LiftOffForBoneHealth, an online public awareness campaign in cooperation with the European Space Agency (ESA)
• In August 2021, Enzene Biosciences, a technology driven company based in Pune, India, announced marketing authorization from the Drug Controller General of India (DCGI) for its third biosimilar drug 'Denosumab', indicated for the treatment of osteoporosis in adults
• In January 2021, Theramex, a global pharmaceutical company, launched Livogiva, a new teriparatide pre-filled pen for the treatment of severe osteoporosis in Europe.

*Definition: Osteoporosis is characterized by reduction in the density and quality of bones that often result in broken bones in the wrist, hip, and spine. Various factors responsible for osteoporosis include, genetic factors, low intake of calcium, magnesium, and vitamin D, eating disorders such as anorexia, inactivity and immobility, and excessive alcohol intake. Moreover, conditions that increase the risk of osteoporosis include, cancer, chronic kidney diseases, chronic obstructive pulmonary disease, and some autoimmune diseases such as rheumatoid arthritis.

Market Segmentation

•  Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Bisphosphonates 
  • Calcitonin, Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Others
•  Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Injectable
  • Others
•  Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Teva Pharmaceutical Industries Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Amgen Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Viatris Inc.
  • Ligand Pharmaceuticals Incorporated
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • F. Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.